Actimab-Br

N/A

Report date: 2025/03/14 16:20:09

Base Information

Drug NameActimab-Br

Drug Alias Namemonoclonal antibody-actinium radioisotope conjugate (Actinium Pharmaceuticals)

ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsBrain Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsBrain Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A